Wedbush initiated coverage of Wave Life Sciences (WVE) with an Outperform rating and $18 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences’ Promising DMD Treatment Justifies Buy Rating Amid Positive Phase 2 Study Results
- Wave Life Sciences: Buy Rating Affirmed on Promising Clinical Results and Strategic Growth Plans
- Wave Life Sciences Reports Positive Phase 2 Trial Results
- Wave Life Sciences announces data from Phase 2 FORWARD-53 trial of WVE-N531
- Korro Bio price target lowered to $95 from $105 at RBC Capital